FREE MEMBERSHIP Includes » ABL Advisor eNews + iData Blasts | JOIN NOW ABLAdvisor Gray ABLAdvisor Blue
 
Skip Navigation LinksHome / Articles / Read Article

Print

Coherus BioSciences Secures Credit Financing with Pharmakon Advisors

Date: Jan 10, 2022 @ 07:07 AM
Filed Under: Biotechnology

Coherus BioSciences entered into a loan agreement with investment funds managed by Pharmakon Advisors, LP.

“As Coherus enters a period of projected significant topline growth and diversification of our commercial product portfolio, we are pleased to partner with Pharmakon on this new credit facility,” said Denny Lanfear, President and CEO of Coherus. “Strengthening our balance sheet with non-dilutive capital will allow us to maximize shareholder value as we launch as many as five new products in 2022 and 2023.”

The credit facility provides Coherus with up to $300 million committed across four tranches, subject to the terms and conditions of the loan agreement:

  • The first tranche of $100 million was drawn in connection with the close of the transaction, and $81.9 million was used for the simultaneous repayment of the full balance outstanding of Coherus’ previous term loan with HealthCare Royalty Partners.
  • Coherus will draw a second tranche of $100 million no later than April 1, 2022, subject to certain conditions including the conversion, repayment, repurchase or redemption of the Company’s 8.2% Senior Convertible Notes due March 2022.
  • A third tranche of $50 million will become available subject to certain conditions including approval by the U.S. Food and Drug Administration (FDA) of the biologics license application (BLA) for Coherus’ PD-1 inhibitor, toripalimab, for nasopharyngeal carcinoma, currently under priority review with a target action date in April 2022.
  • A fourth tranche of $50 million will become available subject to certain conditions including approval by the FDA of the BLA for CHS-201, a Lucentis® (ranibizumab) biosimilar candidate, currently under review with a target action date of August 2022.

Borrowings under the credit agreement bear interest at 8.25% plus three-month LIBOR per annum with a LIBOR floor of 1.00%. The term loans mature on either (i) the fifth anniversary of the closing date of the first tranche; or (ii) October 15, 2025, if the outstanding aggregate principal amount of the Company’s 1.5% Convertible Senior Subordinated Notes due 2026 is greater than $50.0 million on October 1, 2025. The term loans can be prepaid at Coherus’ discretion at any time, subject to prepayment fees. Repayment of outstanding principle of the term loans will be made in five equal quarterly payments of principle commencing after the 48-month anniversary of the closing date of the first tranche.

Comments From Our Members

You must be an ABL Advisor member to post comments. Login or Join Now.